Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2)

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 1951-1959

  Hank, Jacquelyn A ^a,e   Surfus, Jean E ^a   Gan, Jacek ^a   Jaeger, Peter ^a   Gillies, Stephen D ^b   Reisfeld, Ralph A ^c   Sondel, Paul M ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Fuji ImmunoPharmaceuticals Corp   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; GANGLIOSIDE GD2 ANTIBODY; HYBRID PROTEIN; RECOMBINANT FUSION PROTEIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; MELANOMA; NEUROBLASTOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; IMMUNOTOXINS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030470861     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Rosenberg, S. A., Lotze, A. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., and White, D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474-484, 1989.
2. Weil-Hillman, G., Voss, S. D., Finch, P., Schell, K., Hank, J. A., Sosman, J. A., Sugamura, K., and Sondel, P. M. Natural killer cells activated by Interleukin-2 treatment in vivo respond to Interleukin-2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res., 50: 2683-2691, 1990.
3. Sosman, J. A., Kohler, P C., Hank, J. A., Moore, K. H., Bechhofer, R., Storer, B., and Sondel, P M. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and indomethacin. J. Natl. Cancer Inst., 80: 1451-1460, 1988.
4. Sosman, J. A., Hank, J. A., Moore, K. H., Borchert, A., Schell, K., Kohler, P. C., Goldstein, D., Bechhofer, R., Storer, B., Albertini, M. R., Leung, R., Levitt, D., and Sondel, P. M Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma. Cancer Invest., 9: 35-48, 1991.
5. Phillips, J. H., Gernlo, B. T., Myers, W. W., Rayner, A. A., and Lanier, L. L. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing recombinant interleukin-2 and LAK cell therapy. J. Clin. Oncol., 5: 1933-1941, 1987.
6. McMannis, J. D., Fisher, R. I., Creekmore, S. P., Braun, D. P., Harris, J. E., and Ellis, T. M. In vivo effects of recombinant IL-2. I. Isolation of circulating leul9+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2 J. Immunol., 140: 1335-1340, 1988.
7. 2 antibody plus interleukin-2 induces antibody dependent cellular cytotoxicity against neuroblastoma detected in vitro. J. Immunother., 15: 29-37, 1994.
8. Ziegler, L. D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., Hellstrom, J., Hellstrom, K. E., Nicaise, C., and Dennin, R. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung J. Clin. Oncol., 10: 1470-1478, 1992.
9. Weil-Hillman, G., Fisch, P., Prieves, A. F. Sosman, J. A., Hank, J. A., and Sondel, P. M. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens. Cancer Res., 49: 3680-3688, 1989
10. Gillies, S D , Reilly, E. B., Lo, K M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci USA, 89: 1428-1432, 1992.
11. Sabzevari, H., Gillies, S. D., Mueller, B. M., Pancook, I. D., and Reisfeld, R. A. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA, 91: 9626-9630, 1994.
12. Becker, J. C., Pancook, J. D., Gillies, S. D., Mendelsohn, J., Reisfeld, R. A. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl Acad. Sci. USA, 93: 2702-2707, 1996.
13. Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. T cell mediated eradication of murine metastatic melanoma Induced by targeted Interleukin 2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
14. Gearing, A. J. H., and Thorpe. R The international standard for human interleukin-2. Calibration by international collaborative study. J. Immunol. Methods, 114: 3-9, 1988.
15. Mueller, B. M., Romberdahl, C. A., Gillies, S. D., and Reisfeld, R. A. Enhancement of antibody-dependent cytotoxicity with chimeric anti-GD2 antibody. J. Immunol., 144: 1282-1286, 1990.
16. Gillies, S. D., Young, D., Lo, K-M., Foley, S. F., and Reisfeld, R. A. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma, 10: 347-356, 1991.
17. Sondel, P. M., Kohler, P. C., Hank, J. A., Moore, K. H., Rosenthal, N., Sosman, J., Bechhofer, R , and Storer, B. Clinical and immunological effects of recombinant Interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res., 48: 2561-2567, 1988.
18. c detection and function in YT lymphoid cells and in the GM-CSF responsive human myeloid cell line. Tf-1. Blood. 86: 4568-4578, 1995.
19. Tsudo, M., Kitamura, F., and Miyasaka, M. Characterization of the interleukin 2 receptor B chain using 3 distinct monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 86: 1982-1986, 1989.
20. Hakimi, J., Ha, V. C., Lin, P., Campbell, E., Gately, M. K., Tsudo, M., Payne, P. W., Waldman, T. A., Grant, A, J., and Tsien, W. H. Humanized Mik β 1: a humanized antibody to the IL-2 receptor beta-chain that acts synersistically with humanized anti-TAC. J. Immunol., 151: 1075-1085, 1993.
21. Voss, S. D., Sondel, P. M., and Robb, R. J. Characterization of the Interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R γ chain with the IL-2R γ chain with the Il-2R β chain in functional intermediate-affinity IL-2R. J. Exp. Med., 176: 531-541, 1992.
22. Fell, H. P., Gayle, M. A., Grosmaire, L., and Ledbetter, J. A. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL-2. J. Immunol., 146: 2446-2452, 1991.
23. Hank, J. A., Sosman, J. A., Kohler, P. C., Bechhofer, R., Storer, B., and Sondel, P. M. Depressed in vitro T cell responses concomitant with augmented Interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J. Biol. Response Modif., 9: 5-14, 1990.
24. Hank, J. A. Robinson, R. R., Surfus, J., Mueller, B. M., Reisfeld, R. A., Cheung, N-K., and Sondel, P. M. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant Interleukin-2. Cancer Res., 50: 5234-5239, 1990.
25. Munn, D. H., and Cheung, N. K. V. Interleukin-2 enhancement of monoclonal antibody mediated cellular cytotoxicity against human melanoma. Cancer Res., 47: 6600-6605, 1987.
26. Fearon, E., Pardoll, D., Itaya, T, Golumbeck, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990
27. Gillies, S. D, Young, D., Lo, K-M., and Roberts, S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjugate Chem., 4: 230-235, 1993.
28. Reuland, P., Handgretinger, R., Smykowski, H., Dopfer, R., Klingebiel, T., Miller, B. M., Reisfeld, R. A., Gallagher, S., Koscelniak, E., and Treuner, J. Application of the murine anti-GD-2 antibody 14. GD-2a for diagnosis and therapy of neuroblastoma Intl. J. Radiat. Appl. Instrum. B, 18: 121-125, 1991.
29. Albertini, M. R., Gan, J., Jaeger, P , Hank, J. A., Storer, B., Rivest, T., Surfus, J., Reisfeld, R. A., Schiller, J. H., and Sondel, P. M. Systemic Interleukin-2 treatment can inhibit the anti-idiotypic response to chimeric anti-GD2 antibody in melanoma patients. J. Immunother., in press, 1996.